Related Experiment Video

Updated: May 29, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

Childhood leukodystrophies: a clinical perspective

Alfried Kohlschütter1, Florian Eichler

  • 1Children's Hospital University Medical Center, Hamburg, Germany. kohlschuetter@uke.uni-hamburg.de

Expert Review of Neurotherapeutics
|September 30, 2011
PubMed

Insights

Genetic leukodystrophies, white matter disorders in children, cause progressive neurological disability. Early diagnosis via MRI, clinical clues, and tests is crucial for treatment and management.

Area of Science:

  • Neurology
  • Genetics
  • Radiology

Background:

  • Leukodystrophies are inherited white matter disorders impacting children.
  • These conditions are a significant cause of progressive neurological disability in the young.
  • Accurate identification of leukodystrophies is challenging despite frequent MRI detection.

Purpose of the Study:

  • To highlight the importance of diagnosing leukodystrophies for patient outcomes.
  • To outline the diagnostic strategies for these complex genetic disorders.
  • To emphasize the need for understanding disease pathophysiology for treatment decisions.

Main Methods:

  • Clinical assessment and patient history.
  • Magnetic Resonance Imaging (MRI) pattern recognition.
  • Electrophysiological and laboratory testing.

Main Results:

  • Diagnosis is essential for prognostication and guiding palliative/experimental treatments.
  • Overlap between white and gray matter diseases complicates diagnosis due to secondary myelin loss.
  • Understanding disease progression is key for evaluating treatment risks and benefits.

Conclusions:

  • A multi-faceted diagnostic approach combining clinical, imaging, and laboratory data is necessary.
  • Accurate diagnosis of leukodystrophies is critical for effective patient management and family screening.
  • Further understanding of pathophysiology aids in developing and applying novel therapeutic strategies.

More Related Videos

Mouse Models of Periventricular Leukomalacia06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...